Kalvista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral on-Demand Treatment of Hereditary Angioedema
Kalvista宣佈已提交額外的Sebetralstat治療遺傳性血管性水腫口服即時治療的上市授權申請。
Kalvista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral on-Demand Treatment of Hereditary Angioedema
Kalvista宣佈已提交額外的Sebetralstat治療遺傳性血管性水腫口服即時治療的上市授權申請。
譯文內容由第三人軟體翻譯。